"Captopril" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.
| Descriptor ID |
D002216
|
| MeSH Number(s) |
D12.125.072.401.623.270
|
| Concept/Terms |
Captopril- Captopril
- (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline
SQ-14,534- SQ-14,534
- SQ 14,534
- SQ14,534
- SQ-14534
- SQ 14534
- SQ14534
SQ-14,225- SQ-14,225
- SQ 14,225
- SQ14,225
- SQ-14225
- SQ 14225
- SQ14225
|
Below are MeSH descriptors whose meaning is more general than "Captopril".
Below are MeSH descriptors whose meaning is more specific than "Captopril".
This graph shows the total number of publications written about "Captopril" by people in this website by year, and whether "Captopril" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Captopril" by people in Profiles.
-
Alvin ZV, Laurence GG, Coleman BR, Zhao A, Hajj-Moussa M, Haddad GE. Regulation of the instantaneous inward rectifier and the delayed outward rectifier potassium channels by Captopril and Angiotensin II via the Phosphoinositide-3 kinase pathway in volume-overload-induced hypertrophied cardiac myocytes. Med Sci Monit. 2011 Jul; 17(7):BR165-72.
-
Alvin Z, Laurence GG, Coleman BR, Zhao A, Hajj-Moussa M, Haddad GE. Regulation of L-type inward calcium channel activity by captopril and angiotensin II via the phosphatidyl inositol 3-kinase pathway in cardiomyocytes from volume-overload hypertrophied rat hearts. Can J Physiol Pharmacol. 2011 Mar; 89(3):206-15.
-
Oliveira CR, Paredes-Gamero EJ, Barbosa CM, Nascimento FD, Batista EC, Reis FC, Martins AH, Ferreira AT, Carmona AK, Pesquero JB, Tersariol IL, Ara?jo RC, Bincoletto C. Myelopoiesis modulation by ACE hyperfunction in kinin B(1) receptor knockout mice: relationship with AcSDKP levels. Chem Biol Interact. 2010 Mar 30; 184(3):388-95.
-
Thai HM, Juneman E, Lancaster J, Hagerty T, Do R, Castellano L, Kellar R, Williams S, Sethi G, Schmelz M, Gaballa M, Goldman S. Implantation of a three-dimensional fibroblast matrix improves left ventricular function and blood flow after acute myocardial infarction. Cell Transplant. 2009; 18(3):283-95.
-
Haddad GE, Coleman BR, Zhao A, Blackwell KN. Regulation of atrial contraction by PKA and PKC during development and regression of eccentric cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2005 Feb; 288(2):H695-704.
-
Ray PE, Liu XH, Robinson LR, Reid W, Xu L, Owens JW, Jones OD, Denaro F, Davis HG, Bryant JL. A novel HIV-1 transgenic rat model of childhood HIV-1-associated nephropathy. Kidney Int. 2003 Jun; 63(6):2242-53.
-
Fang Z, Sripairojthikoon W, Calhoun DA, Zhu S, Berecek KH, Wyss JM. Interaction between lifetime captopril treatment and NaCI-sensitive hypertension in spontaneously hypertensive rats and Wistar-Kyoto rats. J Hypertens. 1999 Jul; 17(7):983-91.
-
Mandal TK. Evaluation of a novel phase separation technique for the encapsulation of water-soluble drugs in biodegradable polymer. Drug Dev Ind Pharm. 1998 Jul; 24(7):623-9.